Enovis (NYSE:ENOV) Stock Rating Upgraded by BMO Capital Markets

Enovis (NYSE:ENOV) was upgraded by equities research analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on the company. Zacks Research cut Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 30th. William Blair initiated coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average price target of $41.71.

Enovis Price Performance

Shares of NYSE:ENOV opened at $25.17 on Wednesday. Enovis has a one year low of $19.14 and a one year high of $36.82. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -1.27 and a beta of 1.39. The company has a 50-day simple moving average of $23.34 and a 200-day simple moving average of $23.79. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis will post 3.12 EPS for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders purchased 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after purchasing an additional 621 shares in the last quarter. MGO One Seven LLC increased its holdings in shares of Enovis by 9.4% in the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after purchasing an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. Finally, Inscription Capital LLC lifted its stake in shares of Enovis by 9.4% in the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after purchasing an additional 1,016 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.